Ebglyss Injection, Solution
Product Images NDC 0002-7797

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Ebglyss (NDC 0002-7797). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Ebglyss Ai Ifu 1 V1)

EBGLYSS 250 mg/2mL injection, solution in a prefilled subcutaneous syringe. The syringe is primarily white with a transparent tip and a purple cap. The syringe features dosage markings and a twist-off seal at the plunger end. Labeling indicates Eli Lilly and Company as the manufacturer.*

FDA Label Image

Figure (Ebglyss Ai Ifu 2 V1)

An illustrated diagram of a subcutaneous injection device for EBGLYSS (lebrikizumab-lbkz) 250 mg/2mL. The device features a purple injection button at the top, a lock ring with lock/unlock symbols, a clear base displaying the medicine and needle, and a gray base cap shown separately at the bottom. The diagram labels each part clearly.*

FDA Label Image

Figure (Ebglyss Ai Ifu 3 V1)

An illustration showing a subcutaneous injection device with an arrow pointing to a blacked-out area labeled as the expiration date.*

FDA Label Image

Figure (Ebglyss Ai Ifu 4 V1)

Illustration showing a hand holding an EBGLYSS injection pen for subcutaneous use, labeled with the needle and gray base cap. The diagram indicates the gray base cap being removed by twisting, highlighting needle exposure for injection.*

FDA Label Image

Figure (Ebglyss Ai Ifu 5 V1)

An instructional diagram showing a three-step process for using a subcutaneous injection device. The steps are indicated numerically and include visual cues for removing the cap and administering the injection. The device depicted likely corresponds to the EBGLYSS 250 mg/2 mL injection, solution by Eli Lilly and Company.*

FDA Label Image

Figure (Ebglyss Ai Ifu 6 V1)

An instructional illustration showing a person preparing to administer a subcutaneous injection using the EBGLYSS autoinjector. The image highlights rotating the dial on the injector and the clear base placement against the skin on the abdomen.*

FDA Label Image

Figure (Ebglyss Ai Ifu 7 V1)

Instructional illustration showing a person administering a subcutaneous injection with an autoinjector pen into the abdomen. The image highlights holding the device against the skin for 15 seconds to complete the injection.*

FDA Label Image

Figure (Ebglyss Ai Ifu 8 V1)

An instructional diagram showing a close-up of a syringe's gray plunger, part of a subcutaneous injection device likely related to EBGLYSS (lebrikizumab-lbkz) 250 mg/2 mL solution. The gray plunger is indicated with a black arrow and label.*

FDA Label Image

Figure (Ebglyss Ai Ifu 9 V1)

An instructional illustration showing a hand disposing of a single-dose autoinjector syringe into the top opening of a red sharps disposal container, demonstrating safe injection device disposal.*

FDA Label Image

Figure (Ebglyss Ai Lock)

FDA Label Image

Figure (Ebglyss Ai Unlock)

FDA Label Image

Figure (Ebglyss Ifu Inj Sites 1 V1)

Illustration showing injection site areas on the human body for subcutaneous administration. Highlighted regions include the abdomen around the navel and the front of both thighs, indicating suitable sites for injecting EBGLYSS (lebrikizumab-lbkz) injection, solution.*

FDA Label Image

Figure (Ebglyss Ifu Inj Sites 2 V1)

An instructional diagram showing the posterior view of a human figure indicating subcutaneous injection sites on the outer upper arms (purple shaded areas). The image visually demonstrates proper injection locations for subcutaneous administration.*

FDA Label Image

Carton Image Placeholder (Ebglyss Pen Carton 084 00)

Packaging label for EBGLYSS 250 mg/2 mL (lebrikizumab-lbkz) injection, a human prescription drug by Eli Lilly and Company. The label indicates a single-dose prefilled pen for subcutaneous injection. It includes storage instructions, manufacturer information, and product barcodes.*

FDA Label Image

Carton Image Placeholder (Ebglyss Pfs Carton 9996 02)

EBGLYSS 250 mg/2 mL injection, solution for subcutaneous use. The label shows a single-dose prefilled syringe with needle shield. The product contains the active ingredient lebrikizumab-lbkz and is manufactured by Eli Lilly and Company. The packaging includes storage instructions and barcode details.*

FDA Label Image

Figure (Ebglyss Pfs Ifu 1 V1)

Illustration of a prefilled syringe intended for subcutaneous injection, showing a clear barrel with a purple label band inside and a plunger at one end. The syringe appears to be a delivery device for EBGLYSS (lebrikizumab-lbkz) injection, solution.*

FDA Label Image

Figure (Ebglyss Pfs Ifu 10 V1)

An instructional diagram showing a hand holding a syringe with a needle cap, positioned above a sharps disposal container. The image illustrates the proper disposal method for used syringes and needles, emphasizing safe handling.*

FDA Label Image

Figure (Ebglyss Pfs Ifu 2 V1)

An instructional diagram of a prefilled syringe for EBGLYSS (lebrikizumab-lbkz) injection, solution, 250 mg/2 mL. It shows the syringe components labeled before use: plunger rod, finger grips, syringe with label and expiration date, viewing window, syringe body, needle after removal of needle cap, and a separate needle cap below the syringe.*

FDA Label Image

Figure (Ebglyss Pfs Ifu 3 V1)

An instructional diagram labeled 'After Use' showing a used subcutaneous injection device, including a plunger rod, a syringe with label and expiration date, a used needle, and an activated needle shield. The image highlights components of a used injection syringe, likely for EBGLYSS (lebrikizumab-lbkz) 250 mg/2mL injection.*

FDA Label Image

Figure (Ebglyss Pfs Ifu 4 V1)

An instructional illustration showing a hand holding an injection pen within an open box, indicating how to remove or handle the device by pressing two points marked with red arrows. The image likely pertains to the preparation or use of a subcutaneous injection device for the drug EBGLYSS (lebrikizumab-lbkz).*

FDA Label Image

Figure (Ebglyss Pfs Ifu 5 V1)

An illustration of a subcutaneous injection device for EBGLYSS (lebrikizumab-lbkz) showing labeled parts including the viewing window and the label with expiration date on the syringe barrel. The image highlights key features for proper identification and use of the injection device.*

FDA Label Image

Figure (Ebglyss Pfs Ifu 6 V1)

Illustration showing the preparation of an EBGLYSS (lebrikizumab-lbkz) 250 mg/2 mL subcutaneous injection. It depicts a hand holding a vial and a syringe, with arrows indicating the removal of the vial cap before drawing the solution into the syringe.*

FDA Label Image

Figure (Ebglyss Pfs Ifu 7 V1)

Instructional illustration showing the administration of subcutaneous injection using a syringe at a 45-degree angle, with detailed focus on hand positioning during the injection process.*

FDA Label Image

Figure (Ebglyss Pfs Ifu 8 V1)

Instructional illustration showing the use of a syringe for subcutaneous injection in the thigh area. Includes a zoomed inset detail of the syringe with a purple safety mechanism and a person holding the injection site.*

FDA Label Image

Figure (Ebglyss Pfs Ifu 9 V1)

An instructional illustration showing the use of a prefilled syringe for subcutaneous injection of EBGLYSS (lebrikizumab-lbkz) 250 mg/2mL solution. It depicts a person holding the syringe with one hand positioned on the skin of the thigh or abdomen, demonstrating the injection technique.*

FDA Label Image

Figure 1 (Ebglyss Uspi 1 V1)

Two line graphs titled ADvocate 1 and ADvocate 2 showing the proportion of subjects (%) over 16 weeks comparing EBGLYSS 250mg given every 2 weeks (Q2W) versus placebo. Both graphs show higher proportions of subjects for EBGLYSS compared to placebo at week 16, with values around 43.1% vs 12.7% and 33.2% vs 10.8%, respectively.*

FDA Label Image

Figure 2 (Ebglyss Uspi 2 V1)

A pair of line graphs labeled ADvocate 1 and ADvocate 2 showing the proportion of subjects (%) over weeks treated with EBGLYSS 250 mg every two weeks versus placebo. Both graphs illustrate higher subject response proportions for EBGLYSS compared to placebo over 16 weeks.*

FDA Label Image

Figure (Qr V1)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.